First-line pembrolizumab for lung cancer in a Spanish real-world study.

被引：0
|
作者：
Burgos, Amparo
Calleja, Teresa
Ibanez, Cristina
Maria Valencia, Carmen
Orallo, Claudia
Carlos Titos, Jose
Conde, David
Diaz, Sacramento
Matilla, Belen
Lizeaga, Garbine
Sanchez, Carmen
Marin Pozo, Juan Francisco
Jimenez, Silvia
Jimenez, Inmaculada
Diez, Raul
Garrido, Margarita
Larrosa, Maria
Jose Martinez, Maria
Moreno, Estela
Garcia Campelo, Rosario
机构：
[1] Hosp Univ Dr Balmis Alicante ISABIAL, Alicante, Spain
[2] Hosp Univ La Coruna, La Coruna, Spain
[3] Catalan Inst Oncol Hosp, Oncol Pharm Dept, Lhospitalet De Llobregat, Spain
[4] Hosp Univ Marques de Valdecilla, Santander, Spain
[5] Hosp Univ Asturias, Oviedo, Spain
[6] Hosp Univ Morales Meseguer, Murcia, Spain
[7] Hosp Mar, Barcelona, Spain
[8] Hosp Clin Univ Virgen Arrixaca, Murcia, Spain
[9] Complejo Asistencial Univ Leon, Leon, Spain
[10] Hosp Univ Donostia, San Sebastian, Spain
[11] Hosp Univ Virgen de las Nieves, Granada, Spain
[12] Hosp Univ Jaen, Jaen, Spain
[13] Hosp Univ Salamanca, Salamanca, Spain
[14] Hosp Univ Elche, Elche, Spain
[15] Hosp Univ Getafe, Getafe, Spain
[16] Hosp Virgen Victoria, Malaga, Spain
[17] Hosp Univ Valle Hebron, Barcelona, Spain
[18] Hosp Univ Puerta Mar, Cadiz, Spain
[19] Hosp St Pau & Santa Creu Barcelona, Barcelona, Spain
[20] Hosp Univ A Coruna, La Coruna, Spain
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e23268
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Impact of Frailty on Outcomes of First-Line Pembrolizumab Monotherapy in a Real-World Population with Advanced Non-Small Cell Lung Cancer
    Galan, Rocio Jimenez
    Prado-Mel, Elena
    de Sotomayor, Maria Alvarez
    Martin, Laila Abdel-Kader
    BIOLOGY-BASEL, 2023, 12 (02):
  • [2] Age-Related Outcomes of First-Line Pembrolizumab in a Real-World Non-Small-Cell Lung Cancer (NSCLC) Cohort
    Dolter, S.
    Grosjean, H.
    Meyers, D.
    Javizian, O.
    Stukalin, I.
    Goutam, S.
    Morris, D.
    Bebb, D. G.
    Pabani, A.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S290 - S290
  • [3] Pembrolizumab as first-line treatment for recurrent and metastatic head and neck cancer - real-world single-centre data
    Patachi, Bogdana
    Jensen, Kristian H.
    Gothelf, Anita
    Bernsdorf, Mogens
    Friborg, Jeppe
    Kristensen, Claus A.
    ACTA ONCOLOGICA, 2025, 64 : 143 - 146
  • [4] Real-world cost effectiveness of first-line pembrolizumab for advanced melanoma: A population-based study by the Canadian Real-world Evidence Value for Cancer Drugs (CanREValue) Collaboration.
    Hanna, Timothy
    Aktar, Suriya
    Arciero, Vanessa
    Liu, Ning
    Chan, Kelvin K.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (28) : 17 - 17
  • [5] First-line chemotherapy regimens associated with survival in advanced pancreatic cancer: A Mexican single-center, real-world study.
    Herrera, Marytere
    Diaz, Andrea Maliachi
    Diaz, Consuelo
    Michaus, Veronica Salais
    Ruiz, Erika
    Garcia, Sebastian
    Adame, Sayako Miyagui
    Ruiz, German Calderillo
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : 683 - 683
  • [6] Real-world outcomes of Italian patients with advanced non-squamous lung cancer treated with first-line pembrolizumab plus platinum-pemetrexed
    Leonetti, Alessandro
    Perrone, Fabiana
    Puntoni, Matteo
    Maglietta, Giuseppe
    Bordi, Paola
    Bria, Emilio
    Vita, Emanuele
    Gelsomino, Francesco
    De Giglio, Andrea
    Gelibter, Alain
    Siringo, Marco
    Mazzoni, Francesca
    Caliman, Enrico
    Genova, Carlo
    Bertolini, Federica
    Guaitoli, Giorgia
    Passiglia, Francesco
    Delcuratolo, Marco Donatello
    Montrone, Michele
    Cerea, Giulio
    Pasello, Giulia
    Roca, Elisa
    Belluomini, Lorenzo
    Cecere, Fabiana Letizia
    Guida, Annalisa
    Manzo, Anna
    Adamo, Vincenzo
    Rastelli, Francesca
    Bulotta, Alessandra
    Citarella, Fabrizio
    Toschi, Luca
    Zoratto, Federica
    Cortinovis, Diego Luigi
    Berardi, Rossana
    Follador, Alessandro
    Carta, Annamaria
    Camerini, Andrea
    Salerno, Flavio
    Silva, Rosa Rita
    Baldini, Editta
    Cortellini, Alessio
    Brighenti, Matteo
    Santoni, Matteo
    Malorgio, Francesco
    Caminiti, Caterina
    Tiseo, Marcello
    EUROPEAN JOURNAL OF CANCER, 2024, 202
  • [7] Influence of Performance Status on the Effectiveness of Pembrolizumab Monotherapy in First-Line for Advanced Non-Small-Cell Lung Cancer: Results in a Real-World Population
    Jimenez Galan, Rocio
    Prado-Mel, Elena
    Antonia Perez-Moreno, Maria
    Caballano-Infantes, Estefania
    Flores Moreno, Sandra
    BIOLOGY-BASEL, 2021, 10 (09):
  • [8] First-line treatment in older patients with metastatic colorectal cancer: A large real-world study
    Basile, D.
    Bergamo, F.
    Ongaro, E.
    Cinausero, M.
    Conca, V.
    Ambrosini, M.
    Lucchetti, J.
    Rosati, G.
    Avallone, A.
    Di Paolo, G.
    Lai, E.
    Lutrino, E. S.
    Di Nardo, P.
    Zurlo, I. V.
    Cortese, C.
    Carullo, M.
    Leo, S.
    Di Donato, S.
    Pietrantonio, F.
    Aprile, G.
    ANNALS OF ONCOLOGY, 2024, 35 : S447 - S447
  • [9] Real-world bevacizumab utilization and outcomes in first-line ovarian cancer.
    Monberg, Matthew J.
    Hall, Jennifer P.
    Moon, Rebecca
    Higson, Olivia
    McLaurin, Kimmie
    Dalvi, Tapashi
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [10] UK national real-world outcome data of first-line pembrolizumab treatment in head and neck squamous cell cancer (HNSCC)
    Vasiliadou, I.
    Grose, D.
    Hartley, A.
    Partridge, S.
    Haridass, A.
    Williamson, A.
    Noble, D.
    Walter, H.
    De Winton, E.
    Cohen, J.
    Geropantas, K.
    Donnelly, O.
    Jankowska, P.
    Moleron, R.
    Ulahannan, D.
    Michaelidou, A.
    Raouf, S.
    Khalique, S.
    Bhide, S.
    Kong, A.
    ANNALS OF ONCOLOGY, 2023, 34 : S584 - S584
12345